Skip to main content
. Author manuscript; available in PMC: 2016 Oct 3.
Published in final edited form as: Histopathology. 2011 Jul;59(1):63–72. doi: 10.1111/j.1365-2559.2011.03892.x

Figure 4.

Figure 4

The survival curve showing the recurrence time of 70 patients stratified by Skil and DAB2 protein expression. Even though the P-value is not significant (owing to the relatively small sample size), patients with Skil-positive tumours tend to have longer recurrence times than those with negative Skil expression. On the other hand, patients with DAB2-positive tumours tend to have shorter recurrence times than those with negative DAB2 expression.